ITEM 5 – OTHER INFORMATION
+Added: During the quarter ended March 31, 2024, no director
+Added: or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in
+Added: Item 408(a) of Regulation S-K.
ITEM 6 – EXHIBITS
7 unchanged sentences
Eisenberg, Principal Executive Officer, and James Parslow, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in inline XBRL, include:
+Added: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in inline XBRL, include:
(i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows and (v) the Notes to the Condensed Consolidated Financial Statements.
−Removed: Cover Page Interactive Data File (formatted in inline XBRL and included in Exhibit 101)
+Added: Cover Page Interactive Data File (formatted in XBRL and included in Exhibit 101).
Filed herewith.
4 unchanged sentences
Xenetic Biosciences, Inc.
−Removed: November 9, 2023
/s/ JEFFREY F.
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.